Explore our videos
Owkin CEO Thomas Clozel talks with Insilico CEO Alex Zharanov about AI for healthcare, longevity and labubus.
Discover how next-generation AI transforms routine H&E slides into powerful prognostic insights, helping oncologists personalize treatment and assess relapse risk in early breast cancer.
The MSIntuit Suite features AI-powered solutions for Microsatellite Instability (MSI) screening directly from H&E slides across four cancer types: Colorectal, Endometrial, Gastric, and Biliary. Discover how it works.
Two years on from filming Je Suis Elodie, Elodie talks about how her life has progressed, about how cancer has changed her and her hopes for the future.
A Parisian scientist, who dedicates her life to curing cancer using AI, has a work-life collision when she gets a breast cancer diagnosis.
Owkin collaborates with Baylor, Scott & White to apply AI algorithms to digitized images of endometrial cancer. The project explores molecular changes and aims to improve diagnostic accuracy with AI-driven insights.
Explore how AI agent can leverage large language models and generative AI to better understand biology.
Discover how AI and multimodal data predict YAP1-TEAD activity from histology slides, aiding cancer treatment. Learn about biomarkers, TEAD inhibitors, and clinical applications.
Discover how Owkin and Jewish General Hospital are working with AI and data-driven insights to revolutionize cancer therapy and precision medicine.
Learn how the C Index can be used to evaluate AI model accuracy, from predicting caffeine content in tea to patient survival in cancer research. Raise a cup to better insights!
Discover how Owkin's AI-driven Drug Match Engine finds new uses for existing drugs by analyzing knowledge graphs and patient data. Learn about its innovative machine-learning techniques to predict new indications, patient subgroups, and enhance treatment efficacy.
Owkin's TargetMatch uses 50 petabytes of multimodal data from 30M patients to uncover therapeutic targets. Explore how AI transforms target discovery in hard-to-reach cohorts.
Learn how Owkin’s AI drug pipeline accelerates patient impact by identifying optimal indications and sub-populations for OKN4395, a promising EP2/4 antagonist.
Discover how Owkin’s AI-driven TargetMATCH engine transforms drug discovery by identifying optimal therapeutic targets and patient subgroups. Learn how AI de-risks trials to accelerate treatments.
Understand how MSIntuit® CRC pre-screens for Microsatellite Instability directly from digitized H&E slides.
Explore Owkin’s A to Z of AI in Healthcare—an interactive guide offering bite-sized explanations of AI concepts. Toggle between simple and advanced insights to discover how AI uses patient data to drive healthcare innovations.
Discover MSIntuit CRC, Owkin’s CE-marked AI diagnostic that pre-screens for microsatellite instability using digitized pathology slides. See how AI transforms colorectal cancer diagnosis.
Discover how Owkin's AI technology accelerates drug discovery by combining multimodal patient data and large language models. Our AI uncovers new drug targets, predicts patient outcomes, and de-risks clinical trials, ensuring precision medicine and optimized treatment strategies for the future.
Federated learning enables collaborative research across healthcare institutions while enhancing data privacy. This video explores research on SRATTA, a novel attack on secure aggregation, published at the 2023 International Conference on Machine Learning - and Owkin’s solutions to counter this risk. Learn about strategies to strengthen federated learning defenses, ensuring secure data sharing.
Discover how these models can enhance treatment decisions for oncologists and pathologists.
Artificial intelligence is transforming pathology, enhancing diagnosis precision with tools like Owkin’s MSIntuit CRC. This collaboration between Owkin and Medipath showcases Owkin’s robust solution for pre-screening microsatellite instability (MSI) in colorectal cancer, offering high sensitivity and predictive value. The AI-powered tool supports reliable, timely results, acting as a companion for pathologists.
Discover the groundbreaking MOSAIC program, collecting six modalities, including spatial omics data, from thousands of cancer patients. Explore how spatial biology can dissect tumors at the molecular level, enabling precision medicine and innovative drug development.
Discover how Owkin leverages multimodal patient data as well as innovative and interpretable AI to accelerate drug discovery and precision medicine.
Explore how AI diagnostics transform healthcare, highlighting the people behind innovation in science, medicine, and technology.
Professor Miriam Merad discusses the future of precision medicine, the role of AI in drug discovery, and the importance of healthcare partnerships in advancing cancer treatment.
Discover how our deep learning models can predict patient responses in oncology trials, to increase probability of success and accelerating drug development.
Spatial omics quantifies RNA and protein expression within tissues, offering insights into cell activity in natural contexts. Discover its transformative role, from single-cell RNA sequencing to imaging techniques, as it advances automation, standardization, and ease of use for researchers.
Discover Flamby, a standardized Federated Learning-ready data suite, built for healthcare research. This open-source repository enhances AI models with real-world data, covering modalities like CT scans, MRI, histopathology, and more.
Owkin’s SecureFedYJ algorithm is designed to improve secure federated learning in healthcare, where AI models are trained without centralizing data. SecureFedYJ efficiently normalizes clinical data across hospitals while maintaining privacy.
AI may soon help doctors diagnose diseases like cancer and depression using voice analysis. In an innovative study, 12 institutions, including Owkin, are training machine learning models on voice data to establish the voice as a key clinical biomarker.
PULS-AI is a project to predict patient outcomes for those on anti-angiogenic treatments. Using machine learning across multiple data modalities, the Pulse AI model provides reliable risk stratification, identifying new biomarkers and enhancing personalized care for cancer patients.
Discover how Owkin leverages federated learning to advance drug development and improve patient outcomes. By enabling secure collaboration between hospitals, research centers, and tech partners, Owkin can leverage patient data to build predictive models for personalized cancer treatments while prioritizing privacy.
Discover how covariate adjustment enhances statistical power in oncology trials, improving analysis and accelerating patient recruitment.
Owkin leverages AI to provide pathologists and oncologists with deeper insights into cancer. Our deep learning models analyze digital pathology slides, enhancing diagnostics by predicting molecular phenotypes and patient outcomes. By optimizing workflows, these models can enable faster, precise diagnoses, advancing targeted therapies for better patient outcomes.
Discover how AI biomarkers transform precision medicine by predicting treatment responses, assessing relapse risk, and optimizing diagnostics. Using digital pathology, artificial intelligence and genomics, we accelerate drug research, improve patient outcomes, and enable tailored treatment strategies.
